BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SH, Das K, Noreen S, Coffman F, Hameed M. Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007;5:17. [PMID: 17286869 DOI: 10.1186/1477-7819-5-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Hao H, Chen H, Xie L, Liu H, Wang D. LncRNA KCNQ1OT1 Promotes Proliferation, Invasion and Metastasis of Prostate Cancer by Regulating miR-211-5p/CHI3L1 Pathway. Onco Targets Ther 2021;14:1659-71. [PMID: 33688211 DOI: 10.2147/OTT.S288785] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
3 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
4 Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol. 2008;181:5167-5173. [PMID: 18802121 DOI: 10.4049/jimmunol.181.7.5167] [Cited by in Crossref: 145] [Cited by in F6Publishing: 153] [Article Influence: 10.4] [Reference Citation Analysis]
5 Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105:1203-1209. [PMID: 21934681 DOI: 10.1038/bjc.2011.347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
6 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
7 Lai T, Wu D, Chen M, Cao C, Jing Z, Huang L, Lv Y, Zhao X, Lv Q, Wang Y, Li D, Wu B, Shen H. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling. Respir Res 2016;17:31. [PMID: 27013031 DOI: 10.1186/s12931-016-0338-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
8 Oh IH, Pyo JS, Son BK. Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer. Curr Oncol 2021;28:3139-49. [PMID: 34436040 DOI: 10.3390/curroncol28040274] [Reference Citation Analysis]
9 Wan G, Xiang L, Sun X, Wang X, Li H, Ge W, Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget 2017;8:5382-91. [PMID: 28036271 DOI: 10.18632/oncotarget.14280] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
10 Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
11 Lai T, Chen M, Deng Z, L Y, Wu D, Li D, Wu B. YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment. BMC Pulm Med 2015;15:1. [PMID: 25578181 DOI: 10.1186/1471-2466-15-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
12 Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 2009;11:73-80. [PMID: 19080745 DOI: 10.1007/s11912-009-0012-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
13 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
14 Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75. [PMID: 24634660 DOI: 10.3389/fphys.2014.00075] [Cited by in Crossref: 244] [Cited by in F6Publishing: 263] [Article Influence: 30.5] [Reference Citation Analysis]
15 Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M. Pathway analysis of primary central nervous system lymphoma. Blood 2008;111:3200-10. [PMID: 18184868 DOI: 10.1182/blood-2007-10-119099] [Cited by in Crossref: 118] [Cited by in F6Publishing: 99] [Article Influence: 8.4] [Reference Citation Analysis]
16 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
17 Shao J, Yang X, Ren D, Luo Y, Lai W. A genetic variation in CHI3L1 is associated with bronchial asthma. Arch Physiol Biochem 2021;127:279-84. [PMID: 31295039 DOI: 10.1080/13813455.2019.1634737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8. [PMID: 19134206 DOI: 10.1186/1471-2407-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
19 Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009;28:4456-4468. [PMID: 19767768 DOI: 10.1038/onc.2009.292] [Cited by in Crossref: 168] [Cited by in F6Publishing: 178] [Article Influence: 12.9] [Reference Citation Analysis]
20 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
21 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
22 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
23 Hoover DJ, Zhu V, Chen R, Briley K, Rameshwar P, Cohen S, Coffman FD. Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells. PLoS One. 2013;8:e62491. [PMID: 23671604 DOI: 10.1371/journal.pone.0062491] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
24 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
25 Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008;112:275-85. [PMID: 18157633 DOI: 10.1007/s10549-007-9870-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
26 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
27 Pan JJ, Ge YS, Xu GL, Jia WD, Liu WF, Li JS, Liu WB. The expression of chitinase 3-like 1: a novel prognostic predictor for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2013;139:1043-1054. [PMID: 23525579 DOI: 10.1007/s00432-013-1415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]